Current Regimens Being Investigated in Chronic Lymphocytic Leukemia
Alexey V. Danilov, MD, PhD, discusses important studies in the chronic lymphocytic leukemia space and questions whether combination or sequential therapy is better for patients with chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, associate professor of medicine at the Oregon Health & Science University, discusses important studies in the chronic lymphocytic leukemia (CLL) space and questions whether combination or sequential therapy is better for patients with CLL.
Danilov says that in this new era of medicine, chemotherapy will be used less, and now the question at hand is whether patients with CLL can achieve deep responses on regimens with finite durations. At the 2019 American Society of Hematology (ASH) Annual Meeting, studies of ibrutinib (Imbruvica) plus venetoclax (Venclexta), and acalabrutinib (Calquence) plus venetoclax, with or without a CD20 antibody, were exhibited.
The AVO study of acalabrutinib, venetoclax, and obinutuzumab (Gazyva) was presented by Benjamin L. Lampson, MD, PhD, and Matthew S. Davids, MD. It demonstrated good efficacy through high response rates and high durability in patients with CLL. There were a percentage of patients with bone marrow minimal residual disease after 6 months, according to Danilov. Nitin Jain, MD, presented patients with treatment naïve CLL who showed high response rates with ibrutinib and venetoclax at ASH.
Danilov wonders if combination therapy is necessary for all patients with CLL or if combination therapy with novel agents can result in prolonged progression-free survival or overall survival compared to single-agent therapy. Longer follow-up is required for combination regimens in clinical trials to determine if physicians should use combination therapy versus sequential therapy.
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
January 24th 2025The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.
Read More
First Dose of CD38-Targeting CAR T-Cell Therapy Administered in AML
January 22nd 2025The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38 and developed using the THANK-uCAR platform, in an investigator-initiated trial in China.
Read More
Deciding on Therapy for a Patient With High-Risk Relapsed CLL
January 20th 2025During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic lymphocytic leukemia who received 1 prior line of therapy in the first article of a 2-part series.
Read More
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
